Alternative Treatments: Identifying Options After FDA Reclassification of Specific Peptides Bergen Total Health FDA Moves to Reevaluate Several Peptides American Med Spa Association An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means Development of 503B Bulks List